Clin2
NCT05983432Possibly a fitRecruiting

Study of BL-B01D1 for advanced lung and other solid tumors

Non Small Cell Lung CancerLung CancerBreast CancerEsophageal CancerSmall Cell Lung CancerNasopharyngeal CancerHead and Neck Squamous Cell CarcinomaProstate Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system, Ear, nose & throat, Hormones & metabolism, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.

This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
470 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these types of advanced cancer that has spread or cannot be surgically removed: non-small cell lung cancer, breast cancer (HER2-negative), esophageal cancer, small cell lung cancer, nasopharyngeal cancer, or head and neck cancer.
  • You have had at least one prior chemotherapy treatment for your advanced cancer.
  • Your daily activity level is good (ECOG score 0 or 1 — you are up and about at least half the day).
  • Your major organs (heart, liver, kidneys, bone marrow) are working well enough as shown by recent blood tests.
  • Any previous cancer treatments' side effects have mostly resolved (except for hair loss, mild nerve tingling, or stable thyroid issues).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05470348Recruiting· Phase 1
Test drug BL-B01D1 for advanced breast and other solid cancers

This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.

Guangzhou, Guangdong
NCT06475300Recruiting· Phase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers

This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.

Guangzhou, Guangdong
NCT07056556Recruiting· Phase 1
Study of BL-M09D1 for advanced lung and other solid tumors

This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.

Shanghai, Shanghai Municipality
NCT06493864Recruiting· Phase 1
BL-B16D1 for advanced breast cancer and solid tumors

This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.

Shanghai, Shanghai Municipality
NCT05956587Recruiting· Phase 2
Testing two study drugs for advanced lung cancer and other tumors

This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.

Chongqing, Chongqing Municipality
NCT06505824Recruiting· Phase 1
Study of BL-M14D1 for advanced lung cancer and other solid tumors

This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.

Shanghai, Shanghai Municipality

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.